CORVUS PHARMACEUTICALS INC
CRVSNASDAQ🏆 #1780 by market capUS Equity
$14.74▲ $1.10 (+7.43%)
Live1h—
24h▲ 7.4%
7d▲ 5.8%
14d▲ 10.8%
30d▼ 5.9%
1y▲ 237.7%
🏦Market Cap
$1.24B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
57
Weak
Trading Snapshot
- Day Range
- $14.65 – $15.02
- 52-Week Range
- $4.12 – $26.95
- Volume
- $3.04B
- Avg Volume
- $2.36B
- Shares Outstanding
- 84.1M
- Next Earnings
- Sep 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $155M
- Last Q Revenue
- $40M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.62
- Dividend Yield
- —
Why Investors Own CRVS
- ✓High-growth profile — revenue up +42.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$155M▲ +47.8% YoY
Gross Margin (TTM)
26.6%▲ +3.2% YoY
Operating Income (TTM)
$35M▲ +47.8% YoY
Free Cash Flow (TTM)
$17M▲ +47.8% YoY
About CORVUS PHARMACEUTICALS INC
A company profile for CORVUS PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
57/100
Analyst Price Target
ⓘAverage Target
$19.56
▲ +32.7% Upside
High Target$23.75
Low Target$16.13
Based on 25 analysts
Latest News & Updates
🚀
CNBC·2h ago
CORVUS PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift CRVS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
CORVUS PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.